News

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

TAMPA, FL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Superlatus Inc. ('Superlatus' or the 'Company') recently merged with TRxADE HEALTH, Inc.…

8 months ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON, AEON WS), a…

8 months ago

Alpha Tau Medical to Participate in September Investor Conferences

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the…

8 months ago

Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections

Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest…

8 months ago

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery…

8 months ago

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company…

8 months ago

STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X

HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

8 months ago

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome  

Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address…

8 months ago

Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer

Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug.…

8 months ago

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

8 months ago